M&A Analysis: Grail's Chinese Merger Wraps Up Busy May
It was a robust month for medtech M&A deal making with 17 deals in May, making it the busiest month of the year to date. The total number of acquisitions beat the number recorded in May last year and picked up slightly from the 14 deals inked in the previous month.
You may also be interested in...
A sub-analysis of the Circulating Cell-free Genome Atlas study show Grail's genome-sequencing technology may be able to detect early-stage lung cancer through DNA signals in the blood.
If the beginning of 2017 was marked by doubts around whether and how the FDA would act with respect to complex diagnostics, we enter 2018 feeling that slow-moving vessel may finally be turning.
The medtech industry grew by 5% last year, with revenues from US- and Europe-based medtechs reaching $364.4bn in 2016. Meanwhile, net income rose by 17% to reach $16bn in 2016, according to Ernst & Young's annual medtech "Pulse of the industry" report, released today to coincide with The MedTech Conference in San Jose. With global funding expanding, in particular in Asia, medtechs are well positioned for growth, but only those willing to embrace the digital revolution are poised to win.